CEDARCURE SLIT-tablet special drug use surveillance

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224132

Enrollment

500

Registered

2018-11-06

Start date

2018-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

investigational material(s) Generic name etc : CEDARCURE SLIT-tablet INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Japanese cedar pollinosis who are diagnosed as having appropriate treatment with CEDARCURE

Exclusion criteria

Exclusion criteria: 1)Patients who have administrated CEDARTOLEN or CEDARCURE in the past 2)Patients contraindicated for CEDARCURE Patients who have gone into shock after administration of CEDARCURE Patients with severe asthma (Administration of CEDARCURE may induce asthmatic attacks)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026